Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells
BACKGROUND The Bowman‐Birk inhibitor (BBI) is a soybean‐derived serine protease inhibitor with demonstrated anticarcinogenic activity in both in vitro and in vivo systems. METHODS The effects of BBI and BBI Concentrate (BBIC), a soybean concentrate enriched in BBI, on cell growth, invasion, and/or s...
Gespeichert in:
| Veröffentlicht in: | The Prostate 2002-02, Vol.50 (2), p.125-133 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 133 |
|---|---|
| container_issue | 2 |
| container_start_page | 125 |
| container_title | The Prostate |
| container_volume | 50 |
| creator | Kennedy, Ann R. Wan, X. Steven |
| description | BACKGROUND
The Bowman‐Birk inhibitor (BBI) is a soybean‐derived serine protease inhibitor with demonstrated anticarcinogenic activity in both in vitro and in vivo systems.
METHODS
The effects of BBI and BBI Concentrate (BBIC), a soybean concentrate enriched in BBI, on cell growth, invasion, and/or survival were evaluated by the sulforhodamine B assay, a colony formation assay, the trypan blue dye exclusion assay and an in vitro invasion assay. The cells used in these studies were normal human prostate epithelial cells and prostate epithelial cell lines derived from embryonic prostate tissue (267B1) or benign prostatic hyperplasia (BPH) tissue (BRF‐55T) and human prostate cancer cells established by Ki‐ras oncogene transfection of 267B1 cells (267B1/Ki‐ras) or from metastatic lesions of human prostate cancer (LNCaP and PC‐3).
RESULTS
BBIC had a statistically significant inhibitory effect on the growth and clonogenic survival of BRF‐55T, 267B1/Ki‐ras, LNCaP, and PC‐3 cells. BBI also inhibited the growth of LNCaP cells and the clonogenic survival of BRF‐55T and 267B1/Ki‐ras cells and decreased the ability of LNCaP cells to invade across reconstituted basement membrane (Matrigel) when PC‐3 cell‐conditioned medium was utilized as the chemoattractant. BBI or BBIC did not affect the growth of normal prostate epithelial cells.
CONCLUSION
BBI and/or BBIC could be a useful agent for treatment of prostate diseases. Prostate 50: 125–133, 2002. © 2002 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/pros.10041 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71420233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71420233</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4951-cde7aa6573d8cf51c74be98cb803e66b5b166aafca7c3d2c81acb617150489be3</originalsourceid><addsrcrecordid>eNp9kM9u1DAQxi0EokvhwgMgX-CAGvDEiZ09tlX_IK1ogQJHa-I4XdOsvdjJbvsSPDNOs7Q3Th75-8033wwhr4F9AMbyj-vg41gV8ITMgM1lluryKZmxXLKsAC73yIsYfzGWIJY_J3sAFQiWw4z8OWlbo_tIfUv7paFHfrtClx3ZcEOtW9ra9j5Q7-h18Nt-eZA-NxitdwcUXUN1552_Ns5qGoewsRvsRqflkEzomKvH3lCztsm7s0nUpuvifeuDqtFpEyblJXnWYhfNq927T76fnlwdn2eLi7NPx4eLTBfzEjLdGIkoSsmbSrclaFnUZl7pumLcCFGXNQiB2GqUmje5rgB1LUBCyYpqXhu-T95NvinF78HEXq1sHBOgM36ISkKRs5zzBL6fQJ3ixmBatQ52heFOAVPj9dW4h7q_foLf7FyHemWaR3R37gS83QEYNXZtSKvb-Mjxosx5USUOJm5rO3P3n5Hq8uvFt3_Ds6nHxt7cPvRguFFCclmqn5_P1OLq8ofIvyzUOf8LxFmu5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71420233</pqid></control><display><type>article</type><title>Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Kennedy, Ann R. ; Wan, X. Steven</creator><creatorcontrib>Kennedy, Ann R. ; Wan, X. Steven</creatorcontrib><description>BACKGROUND
The Bowman‐Birk inhibitor (BBI) is a soybean‐derived serine protease inhibitor with demonstrated anticarcinogenic activity in both in vitro and in vivo systems.
METHODS
The effects of BBI and BBI Concentrate (BBIC), a soybean concentrate enriched in BBI, on cell growth, invasion, and/or survival were evaluated by the sulforhodamine B assay, a colony formation assay, the trypan blue dye exclusion assay and an in vitro invasion assay. The cells used in these studies were normal human prostate epithelial cells and prostate epithelial cell lines derived from embryonic prostate tissue (267B1) or benign prostatic hyperplasia (BPH) tissue (BRF‐55T) and human prostate cancer cells established by Ki‐ras oncogene transfection of 267B1 cells (267B1/Ki‐ras) or from metastatic lesions of human prostate cancer (LNCaP and PC‐3).
RESULTS
BBIC had a statistically significant inhibitory effect on the growth and clonogenic survival of BRF‐55T, 267B1/Ki‐ras, LNCaP, and PC‐3 cells. BBI also inhibited the growth of LNCaP cells and the clonogenic survival of BRF‐55T and 267B1/Ki‐ras cells and decreased the ability of LNCaP cells to invade across reconstituted basement membrane (Matrigel) when PC‐3 cell‐conditioned medium was utilized as the chemoattractant. BBI or BBIC did not affect the growth of normal prostate epithelial cells.
CONCLUSION
BBI and/or BBIC could be a useful agent for treatment of prostate diseases. Prostate 50: 125–133, 2002. © 2002 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.10041</identifier><identifier>PMID: 11816021</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Antineoplastic agents ; Basement Membrane ; benign prostatic hyperplasia ; Biological and medical sciences ; Bowman-Birk inhibitor ; Cell Division - drug effects ; Cell Survival - drug effects ; Chemotactic Factors ; Chemotherapy ; Clone Cells ; Fluorescent Dyes ; Humans ; Male ; Medical sciences ; Neoplasm Invasiveness ; Pharmacology. Drug treatments ; Prostate - cytology ; prostate cancer ; Prostatic Hyperplasia - pathology ; Prostatic Neoplasms - pathology ; Rhodamines ; Trypsin Inhibitor, Bowman-Birk Soybean - pharmacology ; Trypsin Inhibitors - pharmacology ; Tumor Cells, Cultured</subject><ispartof>The Prostate, 2002-02, Vol.50 (2), p.125-133</ispartof><rights>Copyright © 2002 Wiley‐Liss, Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4951-cde7aa6573d8cf51c74be98cb803e66b5b166aafca7c3d2c81acb617150489be3</citedby><cites>FETCH-LOGICAL-c4951-cde7aa6573d8cf51c74be98cb803e66b5b166aafca7c3d2c81acb617150489be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.10041$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.10041$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13452348$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11816021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kennedy, Ann R.</creatorcontrib><creatorcontrib>Wan, X. Steven</creatorcontrib><title>Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>BACKGROUND
The Bowman‐Birk inhibitor (BBI) is a soybean‐derived serine protease inhibitor with demonstrated anticarcinogenic activity in both in vitro and in vivo systems.
METHODS
The effects of BBI and BBI Concentrate (BBIC), a soybean concentrate enriched in BBI, on cell growth, invasion, and/or survival were evaluated by the sulforhodamine B assay, a colony formation assay, the trypan blue dye exclusion assay and an in vitro invasion assay. The cells used in these studies were normal human prostate epithelial cells and prostate epithelial cell lines derived from embryonic prostate tissue (267B1) or benign prostatic hyperplasia (BPH) tissue (BRF‐55T) and human prostate cancer cells established by Ki‐ras oncogene transfection of 267B1 cells (267B1/Ki‐ras) or from metastatic lesions of human prostate cancer (LNCaP and PC‐3).
RESULTS
BBIC had a statistically significant inhibitory effect on the growth and clonogenic survival of BRF‐55T, 267B1/Ki‐ras, LNCaP, and PC‐3 cells. BBI also inhibited the growth of LNCaP cells and the clonogenic survival of BRF‐55T and 267B1/Ki‐ras cells and decreased the ability of LNCaP cells to invade across reconstituted basement membrane (Matrigel) when PC‐3 cell‐conditioned medium was utilized as the chemoattractant. BBI or BBIC did not affect the growth of normal prostate epithelial cells.
CONCLUSION
BBI and/or BBIC could be a useful agent for treatment of prostate diseases. Prostate 50: 125–133, 2002. © 2002 Wiley‐Liss, Inc.</description><subject>Antineoplastic agents</subject><subject>Basement Membrane</subject><subject>benign prostatic hyperplasia</subject><subject>Biological and medical sciences</subject><subject>Bowman-Birk inhibitor</subject><subject>Cell Division - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Chemotactic Factors</subject><subject>Chemotherapy</subject><subject>Clone Cells</subject><subject>Fluorescent Dyes</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Invasiveness</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostate - cytology</subject><subject>prostate cancer</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Rhodamines</subject><subject>Trypsin Inhibitor, Bowman-Birk Soybean - pharmacology</subject><subject>Trypsin Inhibitors - pharmacology</subject><subject>Tumor Cells, Cultured</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9u1DAQxi0EokvhwgMgX-CAGvDEiZ09tlX_IK1ogQJHa-I4XdOsvdjJbvsSPDNOs7Q3Th75-8033wwhr4F9AMbyj-vg41gV8ITMgM1lluryKZmxXLKsAC73yIsYfzGWIJY_J3sAFQiWw4z8OWlbo_tIfUv7paFHfrtClx3ZcEOtW9ra9j5Q7-h18Nt-eZA-NxitdwcUXUN1552_Ns5qGoewsRvsRqflkEzomKvH3lCztsm7s0nUpuvifeuDqtFpEyblJXnWYhfNq927T76fnlwdn2eLi7NPx4eLTBfzEjLdGIkoSsmbSrclaFnUZl7pumLcCFGXNQiB2GqUmje5rgB1LUBCyYpqXhu-T95NvinF78HEXq1sHBOgM36ISkKRs5zzBL6fQJ3ixmBatQ52heFOAVPj9dW4h7q_foLf7FyHemWaR3R37gS83QEYNXZtSKvb-Mjxosx5USUOJm5rO3P3n5Hq8uvFt3_Ds6nHxt7cPvRguFFCclmqn5_P1OLq8ofIvyzUOf8LxFmu5Q</recordid><startdate>20020201</startdate><enddate>20020201</enddate><creator>Kennedy, Ann R.</creator><creator>Wan, X. Steven</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020201</creationdate><title>Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells</title><author>Kennedy, Ann R. ; Wan, X. Steven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4951-cde7aa6573d8cf51c74be98cb803e66b5b166aafca7c3d2c81acb617150489be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antineoplastic agents</topic><topic>Basement Membrane</topic><topic>benign prostatic hyperplasia</topic><topic>Biological and medical sciences</topic><topic>Bowman-Birk inhibitor</topic><topic>Cell Division - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Chemotactic Factors</topic><topic>Chemotherapy</topic><topic>Clone Cells</topic><topic>Fluorescent Dyes</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Invasiveness</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostate - cytology</topic><topic>prostate cancer</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Rhodamines</topic><topic>Trypsin Inhibitor, Bowman-Birk Soybean - pharmacology</topic><topic>Trypsin Inhibitors - pharmacology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kennedy, Ann R.</creatorcontrib><creatorcontrib>Wan, X. Steven</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kennedy, Ann R.</au><au>Wan, X. Steven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2002-02-01</date><risdate>2002</risdate><volume>50</volume><issue>2</issue><spage>125</spage><epage>133</epage><pages>125-133</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>BACKGROUND
The Bowman‐Birk inhibitor (BBI) is a soybean‐derived serine protease inhibitor with demonstrated anticarcinogenic activity in both in vitro and in vivo systems.
METHODS
The effects of BBI and BBI Concentrate (BBIC), a soybean concentrate enriched in BBI, on cell growth, invasion, and/or survival were evaluated by the sulforhodamine B assay, a colony formation assay, the trypan blue dye exclusion assay and an in vitro invasion assay. The cells used in these studies were normal human prostate epithelial cells and prostate epithelial cell lines derived from embryonic prostate tissue (267B1) or benign prostatic hyperplasia (BPH) tissue (BRF‐55T) and human prostate cancer cells established by Ki‐ras oncogene transfection of 267B1 cells (267B1/Ki‐ras) or from metastatic lesions of human prostate cancer (LNCaP and PC‐3).
RESULTS
BBIC had a statistically significant inhibitory effect on the growth and clonogenic survival of BRF‐55T, 267B1/Ki‐ras, LNCaP, and PC‐3 cells. BBI also inhibited the growth of LNCaP cells and the clonogenic survival of BRF‐55T and 267B1/Ki‐ras cells and decreased the ability of LNCaP cells to invade across reconstituted basement membrane (Matrigel) when PC‐3 cell‐conditioned medium was utilized as the chemoattractant. BBI or BBIC did not affect the growth of normal prostate epithelial cells.
CONCLUSION
BBI and/or BBIC could be a useful agent for treatment of prostate diseases. Prostate 50: 125–133, 2002. © 2002 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>11816021</pmid><doi>10.1002/pros.10041</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0270-4137 |
| ispartof | The Prostate, 2002-02, Vol.50 (2), p.125-133 |
| issn | 0270-4137 1097-0045 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71420233 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Antineoplastic agents Basement Membrane benign prostatic hyperplasia Biological and medical sciences Bowman-Birk inhibitor Cell Division - drug effects Cell Survival - drug effects Chemotactic Factors Chemotherapy Clone Cells Fluorescent Dyes Humans Male Medical sciences Neoplasm Invasiveness Pharmacology. Drug treatments Prostate - cytology prostate cancer Prostatic Hyperplasia - pathology Prostatic Neoplasms - pathology Rhodamines Trypsin Inhibitor, Bowman-Birk Soybean - pharmacology Trypsin Inhibitors - pharmacology Tumor Cells, Cultured |
| title | Effects of the Bowman-Birk inhibitor on growth, invasion, and clonogenic survival of human prostate epithelial cells and prostate cancer cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T17%3A16%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20the%20Bowman-Birk%20inhibitor%20on%20growth,%20invasion,%20and%20clonogenic%20survival%20of%20human%20prostate%20epithelial%20cells%20and%20prostate%20cancer%20cells&rft.jtitle=The%20Prostate&rft.au=Kennedy,%20Ann%20R.&rft.date=2002-02-01&rft.volume=50&rft.issue=2&rft.spage=125&rft.epage=133&rft.pages=125-133&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.10041&rft_dat=%3Cproquest_cross%3E71420233%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71420233&rft_id=info:pmid/11816021&rfr_iscdi=true |